3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
30
Neoplasms
5
Lung Neoplasms
4
Uveal Melanoma
2
Melanoma
2
Lymphoma, Large-Cell, Anaplastic
2
Carcinoma
2
ALK-positive NSCLC
2
Solid Tumors
1
Neuroblastoma
1
Multiple Endocrine Neoplasia Type 2a
1
Lymphoma
1
Granuloma, Plasma Cell
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
Advanced Cancer
1
Adenocarcinoma
1
ALK or ROS1-positive NSCLC
1
Interventions
Gemcitabine
22
Fluorouracil
14
Oxaliplatin
13
Capecitabine
13
Paclitaxel
12
pembrolizumab
11
Cisplatin
11
Carboplatin
11
Pemetrexed
10
Leucovorin
9
130-nm albumin-bound paclitaxel
9
Ramucirumab
8
zolbetuximab
7
Albumin-Bound Paclitaxel
7
trastuzumab deruxtecan
6
Drug Therapy
5
Docetaxel
5
Bevacizumab
5
Nivolumab
4
Irinotecan
4
vandetanib
3
cemiplimab
3
Everolimus
3
EC145
3
tislelizumab
2
technetium 99m etarfolatide
2
spartalizumab
2
pralsetinib
2
osimertinib
2
nimotuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma
×
Crizotinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA